-
Allergan
-
Sector
Health Care
-
Industry
Pharmaceuticals
-
Company web
Link
-
Employees
Full Time Employees: 16,700
-
Executives
- Brenton Saunders
- Robert Stewart
- Karen Ling
- James D'Arecca
- William Meury
- C. Nicholson
- A. Robert Bailey
- Christopher Coughlin
- Paul Bisaro
- Joseph Boccuzi
-
Company address
- Clonshaugh Business and Technology Park
- Dublin, D17 E400
- Ireland
- 1-862 261 7000
-
Investor Relation Site
Link
Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women’s health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer’s disease. It is also involved in developing ocular implants that reduce intraocular pressure associated with glaucoma; medical devices for the correction of prominent ears; and intranasal neurostimulation devices, as well as other dry eye products. In addition, the company distributes generic and branded pharmaceutical products primarily to independent and chain pharmacies, nursing homes, mail order pharmacies, hospitals, clinics, and physician offices. Further, it develops a portfolio of breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. The company has licensing agreement with Assembly Biosciences, Inc.; Mimetogen Pharmaceuticals, Inc.; Almirall, S.A; Naurex, Inc.; and Merck & Co. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.
Allergan: Slide deck
- AGN - Q2 Investor Presentation 3 Aug 2017: Slides deck
- AGN - Q1 Investor Presentation 9 May 2017: Slides deck
- AGN - Q4 Annual Report Presentation 8 Feb 2017: Slides deck
- AGN - Q2 Investor Presentation 8 Aug 2016: Slides deck